JZP-169

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[(3R)-3-(2-chlorophenyl)-3-hydroxypropyl]phenyl]amino]butanamide | image = JZP-169_structure.png | width = 250 | alt = | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = | KEGG = | ChEBI = | ChEMBL = | C=18 | H=22 | Cl=1 | N=1 | O=2 | molecular_weight = 319.83 g/mol }}

JZP-169 is an investigational drug developed by Jazz Pharmaceuticals for the treatment of narcolepsy and other sleep disorders. It is a novel compound that acts as a GABA receptor modulator, aiming to improve sleep quality and reduce excessive daytime sleepiness.

Mechanism of Action[edit]

JZP-169 is believed to work by modulating the activity of the gamma-aminobutyric acid (GABA) neurotransmitter system. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its modulation can lead to sedative and anxiolytic effects. JZP-169 enhances the activity of GABA at the GABA_A receptor, which is thought to contribute to its therapeutic effects in sleep disorders.

Clinical Trials[edit]

JZP-169 has undergone several phases of clinical trials to evaluate its safety and efficacy. In Phase I trials, the drug was tested for safety, tolerability, and pharmacokinetics in healthy volunteers. Phase II trials focused on assessing the efficacy of JZP-169 in patients with narcolepsy, measuring outcomes such as sleep latency and overall sleep quality.

Potential Benefits[edit]

The potential benefits of JZP-169 include improved sleep quality, reduced sleep latency, and decreased frequency of cataplexy attacks in patients with narcolepsy. By enhancing GABAergic activity, JZP-169 may help stabilize sleep-wake cycles and improve daytime alertness.

Side Effects[edit]

Common side effects observed in clinical trials include dizziness, headache, and nausea. As with any GABAergic drug, there is a potential for sedation and cognitive impairment, which necessitates careful monitoring and dose adjustment.

Regulatory Status[edit]

As of the latest update, JZP-169 is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Also see[edit]